Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience (Q88697599)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

title

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

Jeffrey P Krischer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

Desmond Schatz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

Kevan C Herold

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

Mark A Atkinson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Cate Speake

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

Jane Buckner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

Peter A Gottlieb

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

publication date

16 May 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

1216-1225

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

Type I diabetes mellitus. A chronic autoimmune disease

26 March 2020

cites work

1 reference

12 December 2020

Evidence for importance of gender and birth cohort for risk of IDDM in offspring of IDDM parents

1 reference

12 December 2020

Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY).

1 reference

12 December 2020

Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop

1 reference

12 December 2020

Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes

1 reference

12 December 2020

Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

1 reference

12 December 2020

Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes

1 reference

12 December 2020

Differential transmission of type 1 diabetes from diabetic fathers and mothers to their offspring

1 reference

12 December 2020

The Environmental Determinants of Diabetes in the Young (TEDDY) Study

1 reference

12 December 2020

Type 1 Diabetes TrialNet--an international collaborative clinical trials network

1 reference

12 December 2020

Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset

1 reference

12 December 2020

Genetics, pathogenesis and clinical interventions in type 1 diabetes

1 reference

12 December 2020

Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1).

1 reference

12 December 2020

Islet autoantibody seroconversion in the DPT-1 study: justification for repeat screening throughout childhood

1 reference

12 December 2020

Metabolic tests to determine risk for type 1 diabetes in clinical trials

1 reference

12 December 2020

How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited

1 reference

12 December 2020

Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young

1 reference

12 December 2020

Early determinants of type 1 diabetes: experience from the BABYDIAB and BABYDIET studies

1 reference

12 December 2020

Development of autoantibodies in the TrialNet Natural History Study

1 reference

12 December 2020

Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes

1 reference

12 December 2020

The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans

1 reference

12 December 2020

Rituximab Selectively Suppresses Specific Islet Antibodies

1 reference

12 December 2020

Effect of rituximab on human in vivo antibody immune responses

1 reference

12 December 2020

Altered B Cell Homeostasis Is Associated with Type I Diabetes and Carriers of the PTPN22 Allelic Variant

1 reference

12 December 2020

1 reference

12 December 2020

Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies

1 reference

12 December 2020

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

1 reference

12 December 2020

Dysregulated Toll-Like Receptor–Induced Interleukin-1β and Interleukin-6 Responses in Subjects at Risk for the Development of Type 1 Diabetes

1 reference

12 December 2020

Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children

1 reference

12 December 2020

Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children

1 reference

12 December 2020

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders

1 reference

12 December 2020

1 reference

12 December 2020

The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells

1 reference

12 December 2020

Diagnosis and Classification of Diabetes Mellitus

1 reference

12 December 2020

Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline

1 reference

12 December 2020

Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes

1 reference

12 December 2020

Analysis of β-cell death in type 1 diabetes by droplet digital PCR.

1 reference

12 December 2020

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.

1 reference

12 December 2020

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes

1 reference

12 December 2020

Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients.

1 reference

12 December 2020

β cell death and dysfunction during type 1 diabetes development in at-risk individuals

1 reference

12 December 2020

The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study

1 reference

12 December 2020

Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY).

1 reference

12 December 2020

Organ donor specimens: What can they tell us about type 1 diabetes?

1 reference

12 December 2020

A run on the biobank: what have we learned about type 1 diabetes from the nPOD tissue repository?

1 reference

12 December 2020

T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.

1 reference

12 December 2020

Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes

1 reference

12 December 2020

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association

1 reference

12 December 2020

Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes.

1 reference

12 December 2020

Rituximab does not reset defective early B cell tolerance checkpoints

1 reference

12 December 2020

The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes

1 reference

12 December 2020

HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression

1 reference

12 December 2020

β-cell Mass in Nondiabetic Autoantibody-Positive Subjects: An Analysis Based on the Network for Pancreatic Organ Donors Database

1 reference

12 December 2020

A model-based approach to sample size estimation in recent onset type 1 diabetes

1 reference

12 December 2020

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants

1 reference

12 December 2020

Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis

1 reference

12 December 2020

Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes

1 reference

12 December 2020

The DIPP project: 20 years of discovery in type 1 diabetes.

1 reference

12 December 2020

Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.

1 reference

12 December 2020

Type 1 Diabetes Prevention: A Goal Dependent on Accepting a Diagnosis of an Asymptomatic Disease

1 reference

12 December 2020

Pre-diagnostic genotyping identifies T1D subjects with impaired Treg IL-2 signaling and an elevated proportion of FOXP3 IL-17 cells

1 reference

12 December 2020

Increase in Pancreatic Proinsulin and Preservation of β-Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset

1 reference

12 December 2020

The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies

1 reference

12 December 2020

β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice

1 reference

12 December 2020

Heterogeneity of the Pancreatic Beta Cell

1 reference

12 December 2020

Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes

1 reference

12 December 2020

Can non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?

1 reference

12 December 2020

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives

1 reference

12 December 2020

Primary islet autoantibody at initial seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease heterogeneity

1 reference

12 December 2020

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

1 reference

12 December 2020

Understanding and preventing type 1 diabetes through the unique working model of TrialNet

1 reference

12 December 2020

Persistence of Pancreatic Insulin mRNA Expression and Proinsulin Protein in Type 1 Diabetes Pancreata

1 reference

12 December 2020

Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes

1 reference

12 December 2020

Assessment of Beta Cell Mass and Function by AIRmax and IVGTT in High Risk Subjects for Type 1 Diabetes

1 reference

12 December 2020

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial

1 reference

12 December 2020

Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes

1 reference

12 December 2020

Identifiers

DOI

10.2337/DB18-0065

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29769238 AND SRC:MED&resulttype=core&format=json

26 March 2020

PubMed publication ID

29769238

1 reference